

CHAPTER VI

REFERENCES

- Abdel H. 2009. Update to risk factors for hepatocellular carcinoma. *International Journal of Medicine and Medical Sciences* Vol 1.(3) pp. 038-043.
- Ashem B., Andrew C., Mason. 1999. Rising incidence of hepatocellular carcinoma in the United States. *N Engl J Med* volume 340, number 10.
- Behne T., Sitki M. 2012. Review article biomarkers for hepatocellular carcinoma. *International Journal of Hepatology* Volume 2012, Article ID 859076, 7 pages.
- Chaur-Shine Wang, Chih-Lin Lin, Hsi-Chang Lee. 2005. Usefulness of serum des- γ -carboxy prothrombin in detection of hepatocellular carcinoma. *World J Gastroenterol* 2005;11(39):6115-6119
- Erick Y., Claessens., François J. 2007. Diagnosis and treatment of severe sepsis. *Critical Care* 2007, 11(Suppl 5):S2
- Gomma AI., Khan SA., Toledano MB., Waked I., Taylor-Robinson SD. 2008. Hepatocellular carcinoma: Epidemiology, risk factors and pathogenesis. *World J. Gastroenterol* 14(27): 4300-8.
- Guo RP., Zhong C., Shi M., Zhang CQ., Wei W. et al. 2006. Clinical value of apoptosis and angiogenesis factors in estimating the prognostic of hepatocellular carcinoma. *J Cancer Res Clin Oncol* 132: 547-55.
- Hanan Abdel H., El Kateb S. 2007. Evaluation of the Diagnostic and Prognostic Value of AFP, PIVKA-II, VEGF and TGF- β 1 in the Diagnosis and Follow up of patients with hepatocellular carcinoma. *Arab J Gastroenterol* 2007; 8(3): 84-89
- Intekhab Alam, Razaullah, Iqbal Haider, M Humayun, M Amjad Taqweem. 2005. Spectrum of precipitating factors of hepatic encephalopathy in liver cirrhosis. *Pakistan J. Med. Res.* Vol. 44, No. 2.
- International guidelines for management of severe sepsis and septic shock: 2008. *Critical Care Medicine* 2008 Vol.36 (1)
- Jayat A., Gregory J., 2004. Diagnosis and Staging of hepatocellular carcinoma. *Gastroenterology*. 2004;127:S126-S132

- Jianjun Z., Jingqun H., Jianqiang C., Xiaojie Y., Zhihun Y. 2003. Vascular endothelial growth factor expression in serum of patients with hepatocellular carcinoma. *Chinese Medical Journal*. 116(5):772-6.
- John M., Ebos., Christina R., Lee.2008. Vascular endothelial growth factor mediated decrease in plasma soluble vascular endothelial growth factor receptor-2 levels as a surrogate biomarker for tumor growth. *American Association for Cancer Research*:68:521-529,2008
- Karlsson S.,Pettila V. 2008.Vascular endothelial growth factor in severe sepsis and septic shock. *International Anesthesia Research Society* DOI: 10.1213
- Narayan A., Bhatt., Mathur R., Farooque A.2010.Cancer biomarkers - Current perspectives. *Indian J Med Res* 132. pp 129-149
- Osama N., Assal E., Yamanoi A.1998.Clinical significance of microvessel density and vascular endothelial growth factor expression in hepatocellular carcinoma and surrounding liver: possible involvement of vascular endothelial growth factor in the angiogenesis of cirrhotic liver. *Hepatology* Vol. 27, No. 6
- Parkin DN, 2006. The global health burden of infection associated cancer in year 2002. *Int.J.cance* 118 : 3030-3040
- Pircher A., Hilbe W ., idegger I. 2011. Biomarkers in tumor angiogenesis and anti-angiogenic therapy. *International Journal of Molecular Sciences* 12, 7077-7099.
- Poon RTP., Ng IOL., Lau C., Zhu LX. 2001. Serum vascular endothelial growth factor predicts venous invasion in hepatocellular carcinoma: a prospective study. *Annal of Surgery*. 233(2):227-35.
- Ronnie Tung-Ping Poon, Cecilia Pik-Yuk Lau, Joanna Wen-Ying Ho, et al. 2003. Tissue factor expression correlates with tumor angiogenesis and invasiness in hepatocellular carcinoma. *Clin Cancer Res* 2003;9:5339-5345.
- Schoenleber SJ., Kurts DM., Talealkar JA., Roberts LR., Gores GJ. 2009. Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis. *British Journal of Cancer*. 100:1385-92.

- Shariff MI., Cox IJ., Gomaa AI., Khan SA., Gedroyc W., Taylor-Robinson SD. 2009. Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnostic and therapeutics. *Expert Rev Gastroenterol Hepatol.* 3(4): 353-67.
- Sun HC., Tang ZY. 2004. Angiogenesis in hepatocellular carcinoma: the retrospsctive and perspective. *J Cancer Res Clin Oncol* 130:307-19.
- Wang G., Zhou X.2010.Relationship Between Serum Heparanase and Microscopic Venous Invasion in Patients With Hepatocellular Carcinoma. *Am J Clin Pathol* 2010;134:242-248
- Wiwanitkit V. 2005. Alpha fetoprotein for screening for hepatocellular cancer in populations with viral hepatitis b: an appraisal of thai reports. *Asian Pacific J Cancer Prev*, 6, 535-536
- Yang ZF., Poon RTP. 2008. Vascular change in hepatocellular carcinoma. *The Anatomical Record.* 291:721-34.
- Yao DF., Wu XH., Zhu Y., Shi GS., Dong ZZ. et al. 2005. Quantitative analysis of vascular endothelial growth factor, microvascular density and their clinicopathologic features in human hepatocellular carcinoma. *Hepatobiliary Pancreas Dis Inf.* 4: 220-6.
- Yim H., Chung J.2009. An overview of biomarkers and molecular signatures in hcc. *cancers journal* 2, 809-823.
- Yoshiji H.,Noghuci R.,Ikenaka Y., Kaji K. 2010 Soluble VEGF receptor-2 may be a predictive marker of anti-angiogenic therapy with clinically available safe agents. *Oncology Letter* 2: 69-73, 2011